The first-in-human clinical trial using CD33 CAR-NK cells derived from engineered NK-92 cells on three relapse/refractory extramedullary AML patients had no encouraging results (1/3 reached a transitory complete remission of 4 months) (44). The gene discussed is CD33; the disease is acute myeloid leukemia.